Financial Performance - The company's operating revenue for Q1 2024 was CNY 4,142,160,958.07, representing a year-on-year increase of 5.36%[4] - The net profit attributable to shareholders was CNY 176,741,385.26, reflecting a significant increase of 44.52% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 159,290,806.61, up by 43.11% year-on-year[4] - Basic earnings per share increased by 40.00% to CNY 0.07 per share[4] - Total operating revenue for Q1 2024 reached ¥4,142,160,958.07, an increase of 5.35% compared to ¥3,931,549,972.98 in Q1 2023[17] - Net profit for Q1 2024 was ¥190,306,825.92, representing a 36.00% increase from ¥139,987,574.96 in Q1 2023[19] - The net profit attributable to shareholders of the parent company for Q1 2024 was ¥176,741,385.26, compared to ¥122,293,236.02 in Q1 2023, marking a growth of 44.41%[19] - Basic and diluted earnings per share for Q1 2024 were both ¥0.07, up from ¥0.05 in Q1 2023[19] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 14,146,783,796.73, a slight increase of 0.25% from the end of the previous year[5] - The equity attributable to shareholders increased by 3.74% to CNY 4,900,837,590.76 compared to the end of the previous year[5] - As of March 31, 2024, the company's total assets amounted to RMB 14,146,783,796.73, an increase from RMB 14,112,148,916.32 as of December 31, 2023, reflecting a growth of approximately 0.24%[12] - The company's current assets totaled RMB 10,484,467,557.58, compared to RMB 10,396,022,101.31 at the end of 2023, indicating an increase of about 0.84%[12] - Total liabilities as of Q1 2024 amounted to ¥8,533,630,990.83, down from ¥8,689,309,461.28 in the previous year[18] - The total liabilities of the company were RMB 11,000,933,879.06, compared to RMB 11,005,962,440.00 at the end of 2023, showing a marginal decrease of about 0.05%[13] Cash Flow - The net cash flow from operating activities was negative at CNY -270,799,005.53, a decrease of 248.28% year-on-year[4] - In Q1 2024, the net cash flow from operating activities was -270,799,005.53, a decrease from 182,625,091.63 in Q1 2023, indicating a significant decline in operational performance[22] - Total cash inflow from operating activities in Q1 2024 was 3,729,185,278.24, down from 4,022,411,651.90 in Q1 2023, reflecting a year-over-year decrease of approximately 7.3%[22] - Cash outflow from operating activities increased to 3,999,984,283.77 in Q1 2024, compared to 3,839,786,560.27 in Q1 2023, representing an increase of about 4.2%[22] - Cash flow from investing activities showed a net outflow of -14,741,375.45 in Q1 2024, slightly worse than -14,342,365.80 in Q1 2023[23] - Cash inflow from financing activities was 590,000,000.00 in Q1 2024, down from 650,807,640.00 in Q1 2023, indicating a decrease of approximately 9.3%[23] - The net cash flow from financing activities improved to 126,267,552.73 in Q1 2024, compared to 62,865,637.35 in Q1 2023, showing a positive trend[23] Expenses and Costs - The company reduced its financial expenses by 61.26%, amounting to a decrease of CNY 5,100,000, due to effective financing strategies[5] - Total operating costs for Q1 2024 were ¥3,915,903,736.03, up from ¥3,749,463,341.18 in Q1 2023, reflecting a growth of 4.43%[18] - Research and development expenses decreased to ¥25,265,801.00 in Q1 2024 from ¥33,061,277.20 in Q1 2023, a reduction of 23.67%[18] - The company paid 192,394,621.99 in taxes in Q1 2024, down from 240,140,104.18 in Q1 2023, reflecting a reduction of approximately 19.9%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 101,974[8]
哈药股份(600664) - 2024 Q1 - 季度财报